ArticleCancer science2019
Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer.
Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.Radiation oncology (London, England) · 2023Pooled it
- Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease.Journal of radiation research · 2020Pooled it
- Improved Locoregional Recurrence-Free Survival With Carbon Ion Versus Photon Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer.Cancer medicine · 2026Article
- Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and carbon ions irradiation.Molecular and cellular biochemistry · 2026Article
- Validation of the Effectiveness of Visual Feedback Systems in Respiratory Gating Carbon Ion Radiation Therapy.International journal of particle therapy · 2026Article
- Robustness of tumor control (TCP) and normal tissue complication probabilities (NTCP) for intensity modulated particle radiotherapy in locally advanced lung cancer: a scenario-based uncertainty analysis compared to photon radiotherapy (IMRT).Journal of thoracic disease · 2026Article
- Carbon-Ion radiotherapy alone for inoperable locally advanced Non-Small cell lung cancer: A Japanese National registry study (J-CROS-LUNG).Japanese journal of radiology · 2026Observational
- Modern radiotherapy in inoperable locally advanced non-small cell lung cancer: a review of techniques, dose fractionation, and immuno-synergistic strategies.Translational cancer research · 2026Review
- Carbon ion radiotherapy and radiation-induced lung injury: clinical evidence, mechanistic insights, and future directions.Frontiers in oncology · 2026Review
- Effectiveness and safety of carbon ion radiotherapy for stage III non-small cell lung cancer: a single-center retrospective study.Frontiers in oncology · 2026Article
- Comprehensive Robustness Evaluation of Proton and Carbon-Ion Plans in Thoracic Cancer Treatment.International journal of particle therapy · 2025Article
- Recent developments in the field of radiotherapy for the management of lung cancer.Japanese journal of radiology · 2025Review
- Development of a predictive model for radiation pneumonitis based on plasma exosomal miR-200b-5p.Frontiers in oncology · 2025Article
- Early prediction of tumor response to carbon ion radiotherapy viaFrontiers in oncology · 2025Article
- Bone matching versus tumor matching in image-guided carbon ion radiotherapy for locally advanced non-small cell lung cancer.Radiation oncology (London, England) · 2024Article
- Clinical indications and future directions of carbon-ion radiotherapy: a narrative review.Ewha medical journal · 2024Review
- Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study.Journal of radiation research · 2023Article
- Heavy Ion-Responsive lncRNA EBLN3P Functions in the Radiosensitization of Non-Small Cell Lung Cancer Cells Mediated by TNPO1.Cancers · 2023Article
- METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer.Cancer science · 2023Article
- Basic and translational research on carbon-ion radiobiology.American journal of cancer research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy and safety of carbon-ion radiotherapy (CIRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) remain unclear. We reported the clinical outcomes of CIRT for LA-NSCLC. Data for 141 eligible patients who received CIRT between 1995 and 2015 were retrospectively analyzed. Local control (LC), locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. The median age was 75.0 years. Overall, 21 (14.9%), 57 (40.4%), 43 (30.5%) and 20 (14.2%) patients had T1, T2, T3 and T4 disease, respectively. Moreover, 51 (36.2%), 45 (31.9%), 40 (28.4%) and 5 (3.5%) patients had N0, N1, N2 and N3 disease, respectively. Furthermore, 34 (24.1%), 42 (29.8%), 45 (31.9%) and 20 (14.2%) patients had stages IIA, IIB, IIIA and ΙΙΙB disease, respectively. Overall, 62 (44.0%), 60 (42.6%), 8 (5.7%) and 11 (7.8%) patients had adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others, respectively. The median dose was 72.0 Gy (relative biological effectiveness). No patient received concurrent chemotherapy. Median follow-up periods were 29.3 (1.6-207.7) and 40.0 (10.7-207.7) months for all patients and survivors, respectively. Two-year LC, PFS and OS rates were 80.3%, 40.2% and 58.7%, respectively. Overall, 1 (0.7%), 5 (3.5%) and 1 (0.7%) patient developed Grades 4 (mediastinal hemorrhage), 3 (radiation pneumonitis) and 3 (bronchial fistula) toxicities, respectively. Multivariate analysis showed adenocarcinoma and N2/3 classification as significant poor prognosticators of PFS. CIRT is an effective treatment with acceptable toxicity for LA-NSCLC, especially for elderly patients or patients with severe comorbidities who cannot be treated with surgery or chemoradiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.